US2023248736A1PendingUtilityA1

Selective p2x3 modulators

71
Assignee: BELLUS HEALTH COUGH INCPriority: Sep 18, 2017Filed: Sep 14, 2022Published: Aug 10, 2023
Est. expirySep 18, 2037(~11.1 yrs left)· nominal 20-yr term from priority
Inventors:Denis GarceauAntonios MatzouranisRoberto BelliniKemal PayzaNathalie ChauretSusan E. Browne
A61P 27/00A61K 31/5377A61P 11/14A61K 31/437A61K 31/4545
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.

Claims

exact text as granted — not AI-modified
1 . A method of avoiding loss of taste response while treating a chronic cough patient, the method comprising administering to the patient a therapeutically effective amount of a selective P2X3 antagonist, wherein the selective P2X3 antagonist is at least 10-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism. 
     
     
         2 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 20-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism. 
     
     
         3 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 50-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism. 
     
     
         4 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 100-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism. 
     
     
         5 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 500-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism. 
     
     
         6 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 1000-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heterotrimer receptor antagonism. 
     
     
         7 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 2000-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heterotrimer receptor antagonism. 
     
     
         8 . The method of  claim 1 , wherein the selective P2X3 antagonist is at least 2700-fold selective for P2X3 homomeric receptor antagonism versus P2X2/3 heterotrimer receptor antagonism. 
     
     
         9 .- 31 . (canceled)

Join the waitlist — get patent alerts

Track US2023248736A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.